Vericel Corp (OQ:VCEL)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 64 Sidney St
CAMBRIDGE MA 02139-4170
Tel: N/A
IR: See website
Key People
Dominick C. Colangelo
President, Chief Executive Officer, Director
Joseph A. Mara
Chief Financial Officer
Michael Halpin
Chief Operating Officer
Sean C. Flynn
Senior Vice President, General Counsel, Secretary
Jonathan Mark Hopper
Chief Medical Officer
Business Overview
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
Financial Overview
For the three months ended 31 March 2024, Vericel Corp revenues increased 25% to $51.3M. Net loss decreased 48% to $3.9M. Revenues reflect MACI segment increase of 18% to $40.2M, Epicel segment increase of 56% to $10.7M. Lower net loss reflects Interest Income increase from $839K to $1.8M (income), Other expense decrease of 42% to $7K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.16 to -$0.08.
Employees: 314 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,997M as of Mar 31, 2024
Annual revenue (TTM): $207.78M as of Mar 31, 2024
EBITDA (TTM): $1.20M as of Mar 31, 2024
Net annual income (TTM): $0.45M as of Mar 31, 2024
Free cash flow (TTM): $2.04M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 48,601,736 as of Apr 30, 2024
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.